Novo Nordisk Expects 2026 Adjusted Sales Growth Between -5% To -13% At CER

Feb 3 (Reuters) - Novo Nordisk A/S NOVOb.CO:

• NOVO NORDISK RELEASES 2026 SALES AND OPERATING PROFIT OUTLOOK

• NOVO NORDISK - 2026 PROFIT IMPACTED BY USD 4.2 BILLION REVERSAL

• NOVO NORDISK - TO EXPAND WEGOVY ROLL-OUT IN 2026

• NOVO NORDISK - 2026 ADJUSTED SALES GROWTH EXPECTED -5% TO -13% AT CER

• NOVO NORDISK - SALES UP 10%, OPERATING PROFIT UP 6% IN 2025

• NOVO NORDISK OUTLOOK 2026 ADJUSTED OPERATING PROFIT GROWTH IS EXPECTED TO BE -5% TO -13% AT CER

• NOVO NORDISK: EXPECTS TO INTRODUCE WEGOVY 7.2MG DOSE IN A NUMBER OF COUNTRIES IN 2026

Further company coverage: [NOVOb.CO]